JPMorgan Chase & Co. Sells 183,531 Shares of Cellebrite DI Ltd. $CLBT

JPMorgan Chase & Co. lessened its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 21.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 683,842 shares of the company’s stock after selling 183,531 shares during the quarter. JPMorgan Chase & Co.’s holdings in Cellebrite DI were worth $12,672,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of CLBT. Financial Management Professionals Inc. acquired a new stake in shares of Cellebrite DI in the third quarter valued at approximately $28,000. CWM LLC boosted its stake in shares of Cellebrite DI by 85.7% during the 3rd quarter. CWM LLC now owns 1,560 shares of the company’s stock worth $29,000 after acquiring an additional 720 shares during the period. PNC Financial Services Group Inc. increased its holdings in shares of Cellebrite DI by 1,998.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock worth $34,000 after acquiring an additional 1,998 shares during the last quarter. Toth Financial Advisory Corp acquired a new position in shares of Cellebrite DI during the 3rd quarter worth approximately $38,000. Finally, Advisory Services Network LLC bought a new stake in Cellebrite DI in the 3rd quarter valued at $40,000. Institutional investors own 45.88% of the company’s stock.

Analysts Set New Price Targets

CLBT has been the subject of a number of research analyst reports. Needham & Company LLC reduced their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Cellebrite DI Trading Down 6.1%

Cellebrite DI stock opened at $12.95 on Friday. The company has a market capitalization of $3.23 billion, a price-to-earnings ratio of 41.77, a PEG ratio of 2.11 and a beta of 1.30. Cellebrite DI Ltd. has a 12 month low of $11.76 and a 12 month high of $20.53. The stock’s 50 day moving average is $14.52 and its 200-day moving average is $16.75.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, hitting the consensus estimate of $0.14. The business had revenue of $128.82 million during the quarter, compared to analysts’ expectations of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The firm’s revenue for the quarter was up 28.8% compared to the same quarter last year. During the same period last year, the firm posted $0.10 EPS. As a group, equities research analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.